Reversal of cardiac complications by deferiprone and deferoxamine combination therapy in a patient affected by a severe type of juvenile hemochromatosis (JH)

Blood

Volumn 109, Issue 1, 2007, Pages 362-364

  Fabio, Giovanna ^a   Minonzio, Francesca ^a   Delbini, Paola ^a   Bianchi, Annamaria ^a   Cappellini, Maria Domenica ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; CHORIONIC GONADOTROPIN; DEFERIPRONE; DEFEROXAMINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HEPARIN; TESTOSTERONE; WARFARIN;

ADULT; ANAMNESIS; ARTICLE; BLOOD ANALYSIS; CASE REPORT; CLINICAL FEATURE; DRUG DOSE REDUCTION; FAMILY HISTORY; HEART FAILURE; HEMOCHROMATOSIS; HOSPITAL ADMISSION; HUMAN; HYPOGONADISM; MALE; PHLEBOTOMY; PRIORITY JOURNAL; SEXUAL DYSFUNCTION; TREATMENT RESPONSE;

EID: 33846078725     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2006-04-016949     Document Type: Article

References (17)

1. Roetto A, Papanikolaou G, Politou M, et al. Mutant antimicrobial peptide hepcidin is associated with severe juvenile hemochromatosis. Nat Genet. 2003;33:21-22.
2. Delatycki MB, Allen KJ, Gow P, et al. A homozygous HAMP mutation in a multiply consanguineous family with pseudodominant juvenile hemochromatosis. Clin Genet. 2004;65:378-383.
3. Roetto F, Daraio P, Poporato Caruso R, et al. Screening hepcidin for mutations in juvenile hemochromatosis: identification of a new mutation (C70R). Blood. 2004;103:2407-2409.
4. DeGobbi M, Roetto A, Piperno A, et al. Natural history of juvenile haemochromatosis. Br J Haematol. 2002;117:973-979.
5. Porter J, Cary N, Schofield P. Haemochromatosis presenting as congestive heart failure. Br Heart J. 1995;73:73-75.
6. Porter J, Abeysinghe R, Marshall L, Hider R, Singh S. Kinetics of removal and reappearance of non-transferrin-bound plasma iron with deferoxamine therapy. Blood 1996;2:705-713.
7. Cappellini MD, Cohen A, Piga A, et al. A Phase III study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with {beta}-thalassemia. Blood. 2006; 107:3455-3462.
8. Davis BA, Porter JB. Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk beta-thalassemia. Blood. 2000;95:1229-1236.
9. Miskin H, Yaniv I, Berant M, Hershko C, Tamary H. Reversal of cardiac complications in thalassemia major by long-term intermittent daily intensive iron chelation. Eur J Haematol. 2003;70:398-403.
10. Hershko C, Cappellini MD, Galanello R, Piga A, Tognoni G, Masera G. Purging iron from the heart. Br J Haematol. 2004;125:545-551.
11. Anderson LJ, Westwood MA, Holden S, et al. Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2* cardiovascular magnetic resonance. Br J Haematol. 2004;127:348-355.
12. Hershko C, Link G, Konijn AM, Huerta M, Rosenmann E, Reinus C. The iron-loaded gerbil model revisited: effects of deferoxamine and deferiprone treatment. J Lab Clin Med. 2002;139:50-58.
13. Borgna-Pignatti C, Cappellini MD, De Stefano P, et al. Cardiac morbidity and mortality in deferoxamine-or deferiprone-treated patients with thalassemia major. Blood. 2006;107:3733-3737.
14. Pennell DJ, Berdoukas V, Karagiorga M, et al. Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood. 2006;107:3738-3744.
15. Origa R, Bina P, Agus A et al. Combined therapy with deferiprone and desferrioxamine in thalassemia major. Haematologica. 2005;90:1309-1314.
16. Hoffbrand AV, Cohen A, Hershko C. Role of deferiprone in chelation therapy for transfusional iron overload. Blood. 2003;102:17-23.
17. Nielsen P, Fischer R, Buggisch P, Janka-Schaub G. Effective treatment of hereditary haemochromatosis with desferrioxamine in selected cases. Br J Haematol. 2003;123:952-953.